Volver al buscador
FDAFDA · Alimentos y medicamentos·N.º oficial Z-0788-2017

Medtronic SynchroMed II Implantable Drug Infusion System. This system includes: Model 8870 Software Application Card, Model 8840 N'Vision Clinician Programmer, and Model 8637 SynchroMed II Implantable Drug Infusion Pump (supplied in 20 ml or 40 ml reservoir size.) Product Usage: The SynchroMed II Programmable Pump is indicated when patient therapy requires the chronic infusion of the following drugs or fluids: Chronic intraspinal (epidural and intrathecal) infusion of preservative-free morphine sulfate sterile solution in the treatment of chronic intractable pain, Chronic intrathecal infusion of preservative-free ziconotide sterile solution for the management of severe chronic pain, Chronic intrathecal infusion of Lioresal Intrathecal (baclofen Injection ) in the management of serve spasticity, Chronic Intravascular Infusion of Floxuridine (FUDR) or methotrexate for the treatment of primary or metastatic cancer

Publicado el 8 de marzo de 2017 · Inicio del retiro: 3 de octubre de 2016

Resumen

FDA registra el retiro Z-0788-2017 de dispositivos médicos de Clase I, publicado el 8 de marzo de 2017 e iniciado el 3 de octubre de 2016. Empresa responsable: Medtronic Neuromodulation; Estado: Finalizado; Cantidad reportada: 22,298 software cards; Lote: software application cards with versions other than AAU01. La Clase I indica una probabilidad razonable de consecuencias graves para la salud o muerte.

Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.

Qué peligro representa

Medtronic is following up to a May 2013 communication regarding the Priming Bolus function for the SynchroMed Infusion System. Medtronic is updating the Model 8870 software application card (to version AAU01) and the SynchroMed pump labeling to address the priming bolus issue.

Qué hacer

Voluntary: Firm initiated · Visit

Recibe un correo cuando FDA publique un retiro como este

Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.

Detalles del retiro

Fabricante
Medtronic Neuromodulation
Distribuidor
Worldwide Distribution - (US Nationwide) Internationally to Germany, Greece, Australia, United Kingdom, Switzerland, Italy, Norway, France, Canada, and Malta.
Lote
software application cards with versions other than AAU01
Clasificación de riesgo
Class I
Área (FDA)
device
País
United States

Retiros relacionados

Preguntas sobre este retiro

¿Medtronic SynchroMed II Implantable Drug Infusion System. This system includes: Model 8870 Software Application Card, Model 8840 N'Vision Clinician Programmer, and Model 8637 SynchroMed II Implantable Drug Infusion Pump (supplied in 20 ml or 40 ml reservoir size.) Product Usage: The SynchroMed II Programmable Pump is indicated when patient therapy requires the chronic infusion of the following drugs or fluids: Chronic intraspinal (epidural and intrathecal) infusion of preservative-free morphine sulfate sterile solution in the treatment of chronic intractable pain, Chronic intrathecal infusion of preservative-free ziconotide sterile solution for the management of severe chronic pain, Chronic intrathecal infusion of Lioresal Intrathecal (baclofen Injection ) in the management of serve spasticity, Chronic Intravascular Infusion of Floxuridine (FUDR) or methotrexate for the treatment of primary or metastatic cancer fue retirado del mercado?

Sí. FDA publicó el retiro Z-0788-2017 el 8 de marzo de 2017. Peligro reportado: Medtronic is following up to a May 2013 communication regarding the Priming Bolus function for the SynchroMed Infusion System. Medtronic is updating the Model 8870 software application card (to version AAU01) and the SynchroMed pump labeling to address the priming bolus issue.

¿Qué debo hacer si tengo este producto?

Voluntary: Firm initiated · Visit